The ninth version of the Aging Research and Drug Discovery (ARDD) meeting is taking place in Copenhagen from Aug., 29 to Sept. 2, bringing the best speakers to Copenhagen to discuss all aging-related subjects, from technology to the most recent advances in cellular and molecular biology, translated into cutting-edge clinical approaches. This is the best opportunity to hear the most recent breakthroughs from world-leading researchers, clinicians, companies, innovators and investors in the field.
The ARDD meeting has a long history of delivering the best in the field. For its ninth version, it is inviting everyone from all over the globe to join online from Aug. 29 to Sept. 2, 2022. More than 90 speakers from top institutions will be gathered in Copenhagen with thousands watching online. The organization’s mission is to make science more accessible, and now the largest and most essential meeting on aging and drug discovery is just a couple of clicks away.
The nonprofit conference continues to grow every year, hosting more than 2,000 delegates over the past two years and expecting an even bigger attendance this year. To add to the growth, it has developed a new workshop on emerging technologies, which will precede the longevity medicine workshop, tailored to clinicians with an interest in improving their patients’ longevity and quality of life. This is followed by four days packed with amazing speakers as part of the main event. Importantly, the first day is free to join. Attendees will have the chance to ask questions to the speakers via Slack, which will be answered even after the talk is finished.
“Aging is emerging as a druggable condition with multiple pharmaceuticals able to alter the pace of aging in model organisms. The ARDD brings together all levels of the field to discuss the most pressing obstacles in our attempt to find efficacious interventions and molecules to target aging. The 2022 conference is the best yet, with top-level speakers from around the globe. I’m extremely excited to be able to livestream our event from the amazing ceremonial hall here in Copenhagen,” said Dr. Morten Scheibye-Knudsen from University of Copenhagen.
“Aging research is growing faster than ever on both the academia and industry fronts. The ARDD meeting unites experts from different fields and backgrounds, sharing with us their latest groundbreaking research and developments. Our last ARDD meeting took place both offline and online, and it was a great success. I am particularly excited that being a part of the ARDD 2022 meeting will provide an amazing opportunity for young scientists presenting their own work as well as meeting the experts in the field,” said Dr. Daniela Bakula from University of Copenhagen.
“Many credible biopharmaceutical companies have now prioritized aging research for early-stage discovery or therapeutic pipeline development. It is only logical to prioritize therapeutic targets that are important in both aging and age-associated diseases. The patient benefits either way. The best place to learn about these targets is ARDD, which we have been organizing for nine years in a row. This conference is now the largest in the field and is not to be missed,” said Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine and Deep Longevity.
About the Aging Research and Drug Discovery meeting
At ARDD, leaders in the aging, longevity and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging as well as the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, it is expanding this year with a workshop specifically for physicians, where leading knowledge from clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research, and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems. ARRD’s quest is to extend the healthy lifespan of everyone on the planet.
About the Scheibye-Knudsen lab
The Scheibye-Knudsen lab uses in-silico, in-vitro and in-vivo models to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. It has discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
